147
Participants
Start Date
December 21, 2011
Primary Completion Date
February 11, 2015
Study Completion Date
September 14, 2017
Darbepoetin alfa
Administered by subcutaneous injection every 3 weeks
Placebo
Administered by subcutaneous injection every 3 weeks
Research Site, Vienna
Research Site, Brussels
Research Site, Ottignies
Research Site, Leuven
Research Site, Hasselt
Research Site, Liège
Research Site, Linz
Research Site, Basel
Research Site, Salzburg
Research Site, Charleroi
Research Site, Lucerne
Research Site, Innsbruck
Research Site, Haine Saint Paul - La Louviere
Research Site, Bruges
Research Site, Zurich
Research Site, Muensterlingen
Research Site, Roeselare
Research Site, Ghent
Research Site, Sint-Niklaas
Research Site, Athens
Research Site, Athens
Research Site, Caen
Research Site, Alessandria
Research Site, Genova
Research Site, Milan
Research Site, Pátrai
Research Site, Pavia
Research Site, Rotenburg (Wümme)
Research Site, Hanover
Research Site, Toulouse
Research Site, Udine
Research Site, Salamanca
Research Site, Göttingen
Research Site, Bologna
Research Site, Nantes
Research Site, Ioannina
Research Site, Valencia
Research Site, Valencia
Research Site, Zaragoza
Research Site, Cologne
Research Site, Vandœuvre-lès-Nancy
Research Site, Pisa
Research Site, Thessaloniki
Research Site, Pesaro
Research Site, Mannheim
Research Site, Lyon
Research Site, Lyon Cédex 3
Research Site, San Giovanni Rotondo FG
Research Site, Paris
Research Site, Paris
Research Site, Avignon
Research Site, Rionero in Vulture PZ
Research Site, Ulm
Research Site, Reggio Calabria
Research Site, Palermo
Research Site, Bobigny
Research Site, Regensburg
Research Site, Pontoise
Research Site, Brno
Research Site, Hradec Králové
Research Site, Olomouc
Research Site, Ostrava-Poruba
Research Site, Prague
Research Site, Prague
Research Site, Prague
Research Site, Prague
Research Site, Zlín
Research Site, Nice
Research Site, Dresden
Research Site, Leipzig
Research Site, Roma
Research Site, Barcelona
Lead Sponsor
Amgen
INDUSTRY